News
Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.
13m
HealthDay on MSNCertain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist TreatmentFor adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...
Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...
Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.
Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...
3h
Zacks Investment Research on MSNNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
Explore more
Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...
Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...
There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...
Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, ...
Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.
New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results